A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Sponsors

Lead Sponsor: Novo Nordisk A/S

Source Novo Nordisk A/S
Brief Summary

This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and tolerability of semaglutide in healthy male Japanese and Caucasian subjects.

Overall Status Completed
Start Date May 21, 2014
Completion Date October 20, 2014
Primary Completion Date October 20, 2014
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Area under the plasma semaglutide concentration−time curve During a dosing interval (0−168 hours) at steady state
Secondary Outcome
Measure Time Frame
Maximum observed plasma semaglutide concentration at steady state 0−168 hours after the last dose of semaglutide (0.5 and 1.0 mg)
Change in body weight from baseline to the end of treatment Day 1 of Visit 2 (2-21 days after Visit 1), Day 92
Number of treatment emergent adverse events (TEAEs) from baseline to follow-up From Day 1 of Visit 2 (2-21 days after Visit 1) to Day 120−127 (Visit 23)
Enrollment 44
Condition
Intervention

Intervention Type: Drug

Intervention Name: semaglutide

Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule

Intervention Type: Drug

Intervention Name: placebo

Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.

Eligibility

Criteria:

Inclusion Criteria:

- Healthy male Japanese and Caucasian subjects

- Age between 20 and 55 years (both inclusive) at the time of signing informed consent

- Body weight of equal to or above 54.0 kg

- Body mass index (BMI) between 20.0 and 25.0 kg/m^2 (both inclusive)

- Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0%

- For Japanese subjects only: both parents Japanese

- For Caucasian subjects only: both parents Caucasian

Exclusion Criteria:

- Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases

- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)

- History of chronic pancreatitis or idiopathic acute pancreatitis

- Calcitonin above or equal to 50 ng/L

- History of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one glass) of wine or Japanese sake, or approximately 20 mL of spirits

- Smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure

- Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior to Visit 2 (randomisation). The use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted

Gender: Male

Minimum Age: 20 Years

Maximum Age: 55 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Global Clinical Registry (GCR, 1452) Study Director Novo Nordisk A/S
Location
Facility: Novo Nordisk Investigational Site
Location Countries

Japan

Verification Date

April 2018

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 4
Arm Group

Label: Semaglutide 0.5 mg

Type: Experimental

Description: Dose-escalation trial

Label: Semaglutide placebo 0.5 mg

Type: Placebo Comparator

Label: Semaglutide 1.0 mg

Type: Experimental

Description: Dose-escalation trial

Label: Semaglutide placebo 1.0 mg

Type: Placebo Comparator

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Double (Participant, Investigator)

Source: ClinicalTrials.gov